597 results about "Anti solvent" patented technology

A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and / or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and / or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

A method of preparing a poly(arylene ether) includes oxidatively polymerizing a monohydric phenol in solution, concentrating the solution by removing a portion of the solvent to form a concentrated solution having a cloud point, Tcloud, and combining the concentrated solution with an anti-solvent to precipitate the poly (arylene ether), wherein the concentrated solution has a temperature of at least about (Tcloud-10° C.) immediately before it is combined with the anti-solvent. The method reduces the formation of undesirably fine particles in the product poly(arylene ether).

A stable amorphous form of rifaximin is disclosed. This form is chemically and polymorphically stable on storage and can be prepared by dissolving rifaximin in a solvent to form a solution, which is precipitated by adding an anti-solvent and isolating of the precipitated amorphous rifaximin as an end product.

Method for preparing a target substance in particulate form, comprising introducing into a particle formation vessel, through separate first and second fluid inlets respectively, (a) a "target solution / suspension" of the substance in a fluid vehicle and (b) a compressed fluid anti-solvent, and allowing the anti-solvent to extract the vehicle so as to form particles of the substance, wherein the anti-solvent fluid has a sonic, near-sonic or supersonic velocity as it enters the vessel, and wherein the anti-solvent and the target solution / suspension enter the vessel at different locations and meet downstream (in the direction of anti-solvent flow) of the second fluid inlet. Also provided is apparatus for use in such a method.

A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and / or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and / or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

The present invention relates to a crystalline carotenoid compound, such as β-carotene, with a purity of at least 95% and with substantially no solvent enclosed in the crystal lattice. The present invention further describes a process to prepare such a highly pure crystalline carotenoid compound from microbial biomass, without the use of a solvent extraction and / or an anti-solvent crystallization process.

A device and process for crystallizing a compound using hydrodynamic cavitation comprising the steps of mixing at least one stream of a solution of such compound to be crystallized with at least one stream of an anti-solvent and passing the mixed streams at an elevated pressure through a local constriction of flow to create hydrodynamic cavitation thereby causing nucleation and the direct production of crystals.

A device and process for crystallizing a compound using hydrodynamic cavitation comprising the steps of mixing at least one stream of a solution of such compound to be crystallized with at least one stream of an anti-solvent and passing the mixed streams at an elevated pressure through a local constriction of flow to create hydrodynamic cavitation thereby causing nucleation and the direct production of crystals. The compound to be crystallized can be, for example, an active pharmaceutical ingredient.

Provided is a compressed anti-solvent technique for manufacture of drug-containing powders for pulmonary delivery. The drug is processed in a cosolvent system including two or more mutually soluble organic solvents. Also provided are powders manufacturable by the manufacture method, including powders of substantially pure drug and powders including a biocompatible polymer for pulmonary sustained drug release applications. Also provided are packaged products including drug-containing powder in a container that is receivable by and operable with a dry powder inhaler to produce an aerosol including dispersed drug-containing particles when the inhaler is actuated.

The invention provides methods of purifying rebaudioside A from a mixture comprising glycosides of the plant Stevia rebaudiana. The methods of the invention are useful for preparing highly pure rebaudioside A compositions from crude Stevia starting compositions that are typically considerably lower in rebaudioside A concentration. The highly pure rebaudioside A compositions are useful as non-caloric sweeteners in edible or chewable compositions such as food, beverages, medicine, candy, chewing gum, and the like.

Preparation of particles of an active substance having a layer of an additive at the particle surfaces, by dissolving both the active substance and the additive in a vehicle to form a target solution, and contacting the target solution with an anti-solvent fluid using a SEDS(TM) particle formation process, to cause the active substance and additive to coprecipitate. The additive is typically a protective additive, in particular a taste and / or odour masking agent. Also provided is a particulate coformulation made by the method, which has a finite gradient in the relative additive concentration, which concentration increases radially outwards from the active-rich core to the additive-rich surface of the particles.

Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

The invention belongs to the technical field of solar cells and particularly relates to a perovskite membrane and a preparation and application method of the perovskite membrane. The perovskite membrane is generated through a two-step method, a PbI2 membrane is prepared through a solution processing method, and thus the technology is simple and efficient. Besides, due to the two-step method, the flatness of the surface of the perovskite membrane is effectively improved, recombination of carriers on the active layer interface is greatly reduced, the anti-solvent performance of the material is effectively improved, and the performance of a device is obviously improved. The perovskite membrane further has the advantages of being simple in preparation technology, low in cost, good in experimental repeatability, suitable for large-scale industrial production and the like.

The invention relates to a method for preparing a stable albumin nanoparticle, and belongs to the technical field of preparation of biomedical materials. The method comprises the following steps: pretreating albumin by using glutathione and cysteine without biotoxicity; opening an intramolecular disulfide bond; precipitating the albumin by using anti-solvents such as alcohol and the like; and carrying out exchange reaction on a sulfydryl-disulfide bond to obtain the albumin nanoparticle containing the intramolecular disulfide bond. The prepared albumin nanoparticle can be used for the delivery of pharmacological active substances and / or diagnostic agents in an organism. The albumin nanoparticle provided by the invention has the advantages that the albumin nanoparticle has good stability under a dilution condition and gives an oxidation reduction response in a reduced environment. Based on the characteristics, the albumin nanoparticle can stably exist in a blood circulation system of the organism, and can carry out a degradation reaction in a cell under the action of reduced glutathione so as to release a wrapped medicine.

A method of fabricating a large-area perovskite film includes steps of: providing a precursor solution on a conductive substrate to form a film, wherein the perovskite is represented by a formula of ABX3, and the solutes of the precursor solution at least comprises A, B and X; and applying an anti-solvent or Infrared light on the film. The fabrication methods of a large-area perovskite film and a perovskite solar cell or module are also disclosed.

The present invention provides organic nanoparticles that include a molecule having a Log P value of about 3 or above, an amphiphilic diblock copolymer or a surfactant, and a pharmaceutically-acceptable hydrophilic polymer. The present invention also provides methods of making these nanoparticles, e.g., by flash nanoprecipitation, with control over particle size and surface properties. The methods of the present invention provide a means for co-precipitating a water-insoluble compound with an amphiphilic stabilizer within a few milliseconds. The nanoparticles of the present invention exhibit high drug loading, e.g., 50% w / w, and can be produced with a mean particle size less than 200 nm and with a narrow particle size distribution.

The invention relates to a method for dissolving cellulose in a CO2 switchable ionic compound or a mixed system composed of a CO2 switchable ionic compound and an organic solvent. Various anti-solvents are added into the system, or a gas is introduced into the system or heating is conducted to destroy the structure of a CO2 switchable solvent. The dissolved cellulose regenerates in various physical structure forms. By adjusting the CO2 pressure, and selecting organic amine or alcohol of cations and anions able to compose a CO2 switchable ionic compound or the structure of an assistant organic solvent, the solubility of cellulose and various properties of the solution can be controlled.

The invention relates to a silicon-based negative electrode material, a preparation method thereof and an application of the silicon-based negative electrode material in a lithium-ion battery. The silicon-based negative electrode material comprises a silicon-based active material and a composite layer, wherein the composite layer coats the surface of the silicon-based active material and is formedby a flexible polymer, flake graphite and a conductive material; and the method comprises the steps of (1) dissolving the flexible polymer into a solvent; (2) adding the flake graphite and the conductive material into a flexible polymer solution obtained in the step (1) under the stirring condition; (3) adding an anti-solvent to a mixed coating solution obtained in the step (2) and stirring; (4)adding the silicon-based active material to the supersaturated mixed coating solution obtained in step (3) under the stirring condition, stirring and separating; and (5) carrying out thermal treatmentto obtain the silicon-based negative electrode material. The silicon-based negative electrode material is simple in preparation method and low in cost, and industrial production is easy to implement;the prepared silicon-based negative electrode material has excellent electrochemical cycle performance and swelling inhibition performance, and the service life of the lithium-ion battery can be prolonged.

The invention relates to a polydopamine interface regulation-based nitramine explosive modified aluminum powder and a preparation method thereof. Micron-sized crystals containing an aluminum powder and a nitramine explosive are prepared by an anti-solvent process, uniform distribution and close contact of the aluminum powder and the nitramine explosive are achieved, and the crystals have the advantages of compact structure, high thermal stability and high density. The adoption of the polydopamine interface regulation-based nitramine explosive modified aluminum powder in an aluminum-containingexplosive reduces the content of an adhesive and additives in a formula, increases the mass fraction of the main explosive, and achieves the purpose of developing high-energy explosives. In addition,a part of the energetic material adopted to replace RDX, HMX, CL-20 and other nitramine explosives in traditional solid propellants improves the energy level of the propellants, improves the problem of too large viscosity of a propellant slurry, caused by the addition of nano-aluminum powder or high-aluminum powder, and optimizes the preparation technology of the propellants.

The invention provides a sphericized epsilon type hexanitrohexaazaisowurtzitane (HNIW) crystal and a preparation method thereof. The preparation method of the sphericized epsilon type hexanitrohexaazaisowurtzitane (HNIW) crystal comprises the following steps: a) dissolving alpha-HNIW, beta-HNIW and gamma-HNIW or mixture of the alpha-HNIW, the beta-HNIW and the gamma-HNIW into a solvent to form a saturated solution of the alpha-HNIW, the beta-HNIW and the gamma-HNIW or the mixture of the alpha-HNIW, the beta-HNIW and the gamma-HNIW; b) adding a crystal growth control agent to the saturated solution and adding an anti-solvent to form a supersaturated solution; and c) adding epsilon-HNIW seed crystals to the supersaturated solution and continuously adding the anti-solvent until all HNIW in the supersaturated solution is released to grow a sphericized epsilon-HNIW crystal. The sphericized epsilon-HNIW crystal does not have sharp edges and corners but has a multi-faceted spherical shape, particle size of 20 to 500 um, chemical purity of 98 to 99.9 percent determined by high performance liquid chromatography, porosity of 0.01 percent to 0.40 percent and 5kg drop hammer impact sensitivity H50 of 26 to 52 centimeters.

A process for making Clopidogrel Bisulfate Form I which comprises dissolving Clopidogrel Bisulfate Form II in a solublizing solvent at room temperature to form a solution; adding an anti-solvent to the said solution till turbid; stirring the said turbid solution; collecting the precipitated solid and drying the final solid product, form I.

The invention discloses a preparation method of an ezetimibe tablet. The preparation method comprises the following steps of (1) dissolving hydroxypropyl cellulose and ezetimibe into ethanol, and dissolving a carrier material mannitol into a water solution; (2) respectively introducing a supercritical carbon dioxide fluid and the two solutions into a coaxial three-channel nozzle by setting the pressure and temperature of the supercritical carbon dioxide fluid to 10-50 MPa and 35-60 DEG C, and acquiring ultrafine granule mixed powder which contains the ezetimibe, the hydroxypropyl cellulose and the mannitol by utilizing the anti-solvent effect of the supercritical carbon dioxide fluid; (3) directly tabletting the ultrafine granule mixed powder and pharmaceutically acceptable auxiliary materials. The method disclosed by the invention can be used for fast dissolving the ezetimibe, can achieve the dissolution rate of the ezetimibe tablet by 95% for 5 minutes and does not contain the surface active agent.

The invention provides a method for preparing sustained-release miniball, which comprises dissolving polypeptides or micromolecular proteins into DMSO, charging the solution into DCM containing PLGA, forming fine particles of the medicament by utilizing anti-solvent, charging the formed suspension into outer aqueous phase, finally volatilizing the organic solvent to obtain slow release microballoons.

The invention discloses a zero dimension perovskite structure luminescent material A4BX6 and a preparation method thereof. The preparation method comprises the steps of utilizing a principle that the solubility of a solute in a precursor solution can be reduced through an anti-solvent, dripping or slowly diffusing the anti-solvent into the precursor solution so as to prepare the zero dimension perovskite structure efficient luminescent material A4BX6 powder or a single crystal, and concretely, dissolving an A-containing halogen compound and a B-containing halogen compound or B-containing oxide into a solvent to obtain the precursor solution; slowly dripping or diffusing the precursor solution into the anti-solvent, and separating out the zero dimension perovskite structure luminescent material A4BX6 from the precursor solution. The method has the advantages that the obtained zero dimension perovskite structure luminescent material A4BX6 has high purity, the luminous efficiency is high, the requirement on the used equipment is simple, and the like.

The invention relates to low-temperature fast-curing epoxide powder paint which comprises the following components in percentage by weight: 45-65% of epoxy resin, 1-5% of polyepoxy active crosslinking agent, 8-18% of curing agent, 0.1-0.5% of curing accelerating agent, 4-30% of precipitated barium sulfate, 4-8% of mica powder, 2-5% of titanium white, 0.5-1.0% of adhesion accelerating agent and assistants. According to the invention, the epoxide powder paint uses a blended resin system of high molecular weight bisphenol A type epoxy resin and novolac epoxy resin; and after being cured by the curing agent, an obtained paint film has the advantages of the epoxy resin such as high adhesion and good alkali resistance and the characteristics of the novolac resin such as favorable water resistance, solvent resistance and acid resistance, and the paint film has favorable heat resistance. Thus, the epoxide powder paint provided by the invention can be adapted to a high-temperature severe-corrosion environment and has favorable market application prospects.